UB-311
Vaccine
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02551809 NCT02551809 · Early Alzheimer's Disease Registry: NCT02551809 | 2 | Tolerability and Safety Profile of UB-311 Assessed Via Recording of Number of Participants With Adverse Events (78 weeks) 2018-08 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Competitive landscape
Other Amyloid-beta drugs
AV-1959R, ACI-24.060, ALZ-101. Compare all 4 Amyloid-beta drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Early Alzheimer's Disease: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| UB-311: this drug | Phase 2 | Vaccine | Amyloid-beta | not yet graded | No reviewed efficacy summary in this indication | |
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | not yet graded | No reviewed efficacy summary in this indication | |
| AV-1959R | Phase 2(overall) | Vaccine | Amyloid-beta | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Obicetrapib | Phase 2 | Small molecule | CETP | not yet graded | No reviewed efficacy summary in this indication | |
| ACI-24.060 | Phase 1/2(overall) | Vaccine | Amyloid-beta | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Pepinemab | Phase 1/2(overall) | Monoclonal antibody | SEMA4D | not yet graded | No reviewed efficacy summary in this indication | |
| ALZ-101 | Phase 1(overall) | Vaccine | Amyloid-beta | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| PMN310 | Phase 1 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.